What factors drove the changes in Xenon Pharmaceuticals's revenue and profit?

What were the key takeaways from Xenon Pharmaceuticals's earnings call?

What is the revenue and EPS growth rate for Xenon Pharmaceuticals year over year?

What guidance did Xenon Pharmaceuticals's management provide for the next earnings period?

What were the key takeaways from Xenon Pharmaceuticals’s earnings call?

What is the market's earnings forecast for Xenon Pharmaceuticals next quarter?

What does Xenon Pharmaceuticals do and what are its main business segments?

Did Xenon Pharmaceuticals beat or miss consensus estimates last quarter?

- **Phase III Milestone**: 380 patients randomized in X-TOLE2, targeting 2026 readout for azetukalner in focal onset seizures.
- **Therapeutic Expansion**: Azetukalner in MDD and BPD trials (X-NOVA2, X-CEED) with Phase I pain programs advancing.
- **Financial Strength**: $555M cash, sufficient for operations into 2027; new CFO driving commercial readiness for 2027 launch.
- **Differentiation**: AZK's QD dosing, no titration, and mood benefits position it for 30-40% U.S. epilepsy market share.


**【CEO Summary Section】**
- **Phase III X-TOLE2 Milestone**: 380 patients randomized (exceeding target of 360), with top line data expected in early 2026 for focal onset seizures. Study powered to detect efficacy and safety for azetukalner.
- **Therapeutic Expansion**: Azetukalner being evaluated in major depressive disorder (MDD) and bipolar depression (BPD) with Phase III trials (X-NOVA2, X-CEED) underway. Preclinical evidence supports Kv7 mechanism for mood benefits.
- **Pipeline Progress**: Nav1.7 inhibitor (XEN1701) and Kv7 modulator (XEN1120) in Phase I studies for pain. Dravet syndrome program shows preclinical efficacy.

**【CMO Clinical Update】**
- **Epilepsy Program**: X-TOLE2 on track for 2026 readout; 48-week open-label extension data to be presented at AES. X-TOLE3 and X-ACKT studies advancing for broader epilepsy indications.
- **Neuropsychiatry Trials**: X-NOVA2 (MDD) and X-CEED (BPD) enrolling patients. Bipolar depression trial (X-CEED) uses MADRS scale, powered to detect 2-point improvement in depressive symptoms.
- **Early-Stage Pain Programs**: Phase I data for XEN1701 and XEN1120 expected in early 2026, with potential Phase II starts in 2026.

**【CFO Financial Update】**
- **Cash Position**: $555.3M as of Q3 2025, sufficient to fund operations into 2027. Strong balance sheet supports multiple late-stage programs.
- **Commercial Readiness**: New CFO (Tucker Kelly) leading strategic planning for azetukalner launch. $2.4B acquisition experience brings expertise to commercialization efforts.

**【Q&A Highlights】**
- **X-TOLE2 Data Release**: Efficacy and safety metrics to mirror Phase II, with detailed analysis for NDA submission. Interim guidance on timing post-double-blind completion.
- **Commercial Strategy**: AZK's QD dosing, no titration, and mood benefits differentiate it from cenobamate. Targeting 2027 launch with 30-40% U.S. market share.
- **Pipeline Risks**: Nav1.7 selectivity and tolerability in Phase I critical for pain program success. Bipolar trial interim analysis may expand sample size if needed.


Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript

- **Phase III Milestone**: X-TOLE2 recruitment complete; targeting 2026 top-line data for FOS indication.
- **Neuropsychiatric Expansion**: Initiated trials for MDD (X-NOVA3) and bipolar depression (X-CEED).
- **Pain Pipeline Progress**: Phase I studies underway for Kv7 (XEN1120) and Nav1.7 (XEN1701) pain candidates.
- **Commercial Readiness**: Experienced CCO Darren Cline leads launch prep; azetukalner shows 33% seizure-free rate in 36-month OLE.
- **Financial Strength**: $624.8M cash balance supports operations into 2027.

**【CEO Summary Section】**
- Completed patient recruitment in the Phase III X-TOLE2 trial for azetukalner in focal onset seizures (FOS), tracking for top-line data in early 2026.
- Expanded azetukalner into neuropsychiatric indications with initiation of X-NOVA3 (MDD) and X-CEED (bipolar depression) trials.
- Advanced early-stage pipeline with Phase I studies for XEN1120 (Kv7 for pain) and XEN1701 (Nav1.7 for pain).
- Cash balance of $624.8M as of Q2 2025, sufficient to fund operations into 2027.

**【CMO Clinical Updates】**
- X-TOLE2 Phase III trial: 360-patient target, 15mg/25mg dose arms, 90%+ statistical power for 25mg vs placebo.
- Bipolar depression trial (X-CEED): 400-patient target, MADRS endpoint, flexibility to expand to 470 patients based on interim analysis.
- Preclinical data supports azetukalner's potential for mood benefits and safety profile in pain.

**【CCO Commercial Strategy】**
- Darren Cline, former GW Pharma leader, to lead commercialization of azetukalner.
- Azetukalner differentiated by: once-daily dosing, no titration, rapid onset, and 36-month OLE data showing 33% seizure-free rate.
- Planning AES 2025 presentations on long-term azetukalner safety and efficacy.

**【Q&A Highlights】**
- NDA filing expected ~6 months after X-TOLE2 top-line data.
- Nav1.7 program (XEN1701) shows no cardiovascular safety signals in preclinical studies.
- Bipolar trial design allows for sample size adjustment; no mania exacerbation observed in preclinical studies.
- Azetukalner's Kv7 mechanism differentiates from Biohaven's MDD candidate with longer clinical data package (800+ patient-years).

Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript

- **Epilepsy Program Milestone**: Azetukalner Phase 3 epilepsy trial (X-TOLE2) nearing completion, with top-line data expected early 2026.
- **MDD Pipeline Progress**: Investigator-sponsored study shows azetukalner's antidepressant activity, supporting Phase 3 MDD trials on track to initiate.
- **Pain and Rare Disease Expansion**: XEN1120 (Kv7 opener) Phase 1 underway; Nav1.1 program targeting Dravet Syndrome with disease-modifying potential.
- **Financial Strength**: $691M cash balance supports multi-program development into 2027; NDA filing anticipated post-Phase 3 epilepsy readout.

**【CEO Opening Remarks】**
- Highlighted progress in azetukalner's Phase 3 epilepsy program (X-TOLE2), nearing patient recruitment completion with top-line data expected early 2026.
- Emphasized azetukalner's potential as a best-in-class anti-seizure medication with novel Kv7 mechanism, targeting unmet needs in epilepsy and neuropsychiatry.
- Expanded pipeline updates: XEN1120 (Kv7 opener for pain) Phase 1 initiation, XEN1701 (Nav1.7 for pain) IND filing, and Nav1.1 program for Dravet Syndrome.

**【CMO Clinical Updates】**
- X-TOLE2 metrics consistent with Phase 2b, with high investigator enthusiasm and rollover rates into open-label extension.
- Investigator-sponsored study (IST) in MDD showed azetukalner's numerically superior efficacy on MADRS and SHAPS vs. placebo, despite small sample size.
- Phase 3 MDD and bipolar depression trials (X-NOVA2/3, X-BD1) on track to initiate by mid-2025.

**【CFO Financial Summary】**
- Q1 2025 revenue: $7.5M from Neurocrine milestone; cash balance: $691.1M, sufficient for operations into 2027.
- Anticipated NDA filing for azetukalner in epilepsy following Phase 3 readout, with concurrent expansion of neuropsychiatric programs.

**【Q&A Key Takeaways】**
- X-TOLE2 enrollment nearing completion; potential 6-month timeline from top-line data to NDA filing.
- IST results reinforce azetukalner's antidepressant activity, with no changes planned to Phase 3 MDD powering.
- Nav1.1 program targeting disease modification in Dravet Syndrome, with IND-enabling studies expected in 2025.
- Bipolar depression trials will include both Type 1 and Type 2 patients, with stratification considerations.


Xenon Pharmaceuticals (XENE)-12 May 25-2025 Q1 Earnings call transcript

- **Epilepsy Lead**: Azetukalner Phase III FOS readout expected H2 2025 with 85% seizure reduction at 36 months in open-label extension.
- **Bipolar Expansion**: Launching Phase III bipolar depression program mid-2025, targeting 4M patients with unmet need.
- **Pipeline Growth**: Multiple IND filings in 2025 for Kv7 and Nav1.1 programs, supported by $754M cash runway into 2027.
- **Competitive Edge**: Azetukalner's rapid onset, no titration, and mood benefits position it as best-in-class epilepsy therapy.

**【CEO Opening Remarks】**
- **2024 Milestones**: Advanced Azetukalner into Phase III epilepsy trials, launched MDD program, and expanded into bipolar depression. Highlighted over 700 patient-years of data in focal epilepsy, showcasing sustained seizure reduction (85% at 36 months) and tolerability.
- **2025 Priorities**: Phase III readout for focal onset seizures (FOS) in H2 2025, NDA filing, and expansion of Azetukalner into bipolar depression. Also, IND filings for early-stage Kv7 and Nav1.1 programs.
- **Strategic Focus**: Lead with Azetukalner in epilepsy, broaden into neuropsychiatry, and expand pipeline with Kv7 and Nav1.7 programs.

**【CFO Financial Update】**
- **Q4 2024 Cash Position**: $754.4M, sufficient to fund operations into 2027. 
- **Key Milestones**: Phase III epilepsy data readout in H2 2025, MDD trials (X-NOVA2, X-NOVA3), and bipolar depression program initiation mid-2025.
- **Pipeline Investment**: R&D expenses to rise due to multiple Phase III studies (epilepsy, MDD, bipolar) and early-stage programs entering IND.

**【CMO Clinical Development】**
- **Azetukalner in Epilepsy**: X-TOLE open-label extension shows 33% of patients seizure-free for ≥1 year. Phase III FOS readout expected H2 2025.
- **Bipolar Depression Expansion**: Phase II/III program to start mid-2025, targeting 4M U.S. patients with unmet need for tolerable, rapid-acting therapies.
- **Nav1.1 Program**: Preclinical data in Dravet syndrome shows seizure suppression, SUDEP protection, and cognitive benefits. IND-enabling studies underway.

**【Q&A Highlights】**
- **Phase III Timing**: FOS readout in H2 2025; enrollment progressing as planned. Bipolar depression Phase III design details to be disclosed pre-enrollment.
- **Competitive Landscape**: Azetukalner's rapid onset, no titration, and mood benefits differentiate it from XCOPRI and generics. Bipolar depression program supported by strong genetic and preclinical rationale.
- **Pipeline Risk Management**: Diversified Kv7 portfolio reduces dependency on single molecule; Nav1.7 pain program targets acute and chronic settings with unique mechanism.

Xenon Pharmaceuticals (XENE)-27 Feb 25-2024 Q4 Earnings call transcript

Xenon Pharmaceuticals (XENE)-12 Nov 24-2024 Q3 Earnings call transcript

Xenon Pharmaceuticals (XENE)-8 Aug 24-2024 Q2 Earnings call transcript

Xenon Pharmaceuticals (XENE)-9 May 24-2024 Q1 Earnings call transcript

Xenon Pharmaceuticals (XENE)-29 Feb 24-2023 Q4 Earnings call transcript

- **Epilepsy Program Momentum**: X-TOLE2 enrollment on track for H2 2024 completion, with potential for faster timelines than Phase 2b X-TOLE. X-TOLE3 and PGTCS trials progressing alongside.
- **MDD Data Watch**: X-NOVA Phase 2 results due in late November, evaluating 10mg/20mg XEN1101 vs placebo in MDD. Clinicians看好 Kv7机制和差异化安全性.
- **Financial Strength**: $639M cash runway into 2026, with focus on executing epilepsy/MDD programs and monitoring partner progress.
- **Key Risk/Reward**: MDD study outcome could expand XEN1101's addressable market, while epilepsy trials remain on critical path to NDA filing.


**【CEO Summary Section】**
- **Epilepsy Program Progress**: Phase 3 trials (X-TOLE2 and X-TOLE3) for focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) are on track, with X-TOLE2 enrollment expected to complete in H2 2024. X-TOLE2 will include more patients than the Phase 2b X-TOLE trial, and the team aims to match or exceed X-TOLE's enrollment pace.
- **MDD Program Update**: Top-line results from the Phase 2 X-NOVA study in MDD are expected in late November to mid-December. The study includes 160+ patients evaluating 10mg and 20mg doses of XEN1101 against placebo, with primary endpoints on MADRS scores and secondary endpoints on SHAPS scores for anhedonia.
- **Market Research Insights**: Clinicians view XEN1101's novel Kv7 mechanism, once-daily dosing, and lack of sexual dysfunction/weight gain as key differentiators in MDD. The AE profile (e.g., dizziness) is considered acceptable if efficacy is demonstrated.
- **Upcoming Milestones**: AES meeting in December will feature long-term X-TOLE open-label extension data, and Neurocrine's Phase 2 data for NBI-921352 in focal onset seizures is expected in November.

**【CFO Financial Commentary】**
- **Financial Position**: Cash and marketable securities of $639.1M as of Q3 2023, sufficient to fund operations into 2026. No GAAP/Non-GAAP financials provided, but focus on cost control and strategic partnerships.
- **Partner Program Updates**: Neurocrine's Phase 2 data for NBI-921352 in focal onset seizures is anticipated in November. Xenon may opt into co-funding Phase 3 development based on data and regulatory interactions.
- **Pipeline Investment**: Resources remain allocated to advancing XEN1101 Phase 3 epilepsy programs and MDD studies, with pediatric formulations and next-gen Kv drugs in preclinical stages.

**【Q&A Highlights】**
- **X-TOLE2 Enrollment Timeline**: Enrollment completion in H2 2024, with 6-8 months from last patient enrolled to top-line data. No specific levers to accelerate timelines beyond current execution.
- **MDD AE Profile**: Clinicians tolerate mild CNS AEs (e.g., dizziness) if efficacy is demonstrated. No significant safety signals reported in X-NOVA to date.
- **Epilepsy/MDD Synergy**: Patients with epilepsy often experience comorbid depression. Long-term X-TOLE data show quality-of-life improvements (e.g., seizure freedom) that could support broader epilepsy/MDD indications.
- **Competitive Landscape**: Xenon's experience in epilepsy trials (largest sponsor of Phase 3 epilepsy studies) and differentiated XEN1101 profile (no titration, early efficacy onset) position it well against competitors.
- **Regulatory Strategy**: FDA alignment on Phase 3 epilepsy program design; potential MDD registration will depend on X-NOVA results and regulatory interactions.


Actual											-0.22	0	-0.25	-0.34	-0.42	-0.51	-0.36	-0.48	-0.35	-0.55	-0.57	-0.57	-0.63	-0.72	-0.73	-0.64	-0.62	-0.75	-0.81	-0.84	-0.83	-1.07	-1.15
Forecast											-0.322	-0.2383	-0.1086	-0.3929	-0.4325	-0.4788	-0.3833	-0.3711	-0.4056	-0.483	-0.52	-0.5849	-0.621	-0.6966	-0.774	-0.7592	-0.6642	-0.7002	-0.8156	-0.8605	-0.8962	-0.9874	-1.1524
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+31.68%	+100.00%	-130.20%	+13.46%	+2.89%	-6.52%	+6.08%	-29.35%	+13.71%	-13.87%	-9.62%	+2.55%	-1.45%	-3.36%	+5.68%	+15.70%	+6.65%	-7.11%	+0.69%	+2.38%	+7.39%	-8.37%	+0.21%

Actual	--	--	--	--	--	--	--	--	--	--	7.08M	13.38M	6.55M	5.16M	4.36M	2.22M	8.12M	3.74M	8.77M	536.00K	132.00K	0	0	0	0	0	0	0	0	0	7.50M	0	0
Forecast	--	--	--	--	--	--	--	--	--	--	4.50M	6.90M	11.66M	3.21M	2.97M	2.72M	10.22M	5.69M	7.74M	4.18M	4.15M	2.91M	615.38K	461.54K	1.56M	2.30M	0	0	0	357.14K	2.71M	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+57.29%	+93.97%	-43.81%	+60.41%	+46.66%	-18.36%	-20.55%	-34.27%	+13.29%	-87.17%	-96.82%	-100.00%	-100.00%	-100.00%	-100.00%	-100.00%	0.00%	0.00%	0.00%	-100.00%	+176.32%	0.00%	0.00%

XENE

XENE fundamentals

XENE Q3 2025 Earnings

Earnings Call

You can ask Aime

XENE

XENE fundamentals

XENE Q3 2025 Earnings

Earnings Call

XENE Earnings Call Summary for Q3/20254:30 PM on Nov 3, 2025

XENE Earnings Call Summary for Q2/20254:30 PM on Aug 11, 2025

XENE Earnings Call Summary for Q1/20254:30 PM on May 12, 2025

XENE Earnings Call Summary for Q4/20244:30 PM on Feb 27, 2025

XENE Earnings Call Summary for Q3/20244:30 PM on Nov 12, 2024

You can ask Aime